Three years of ibrutinib in CLL

Blood

Volumn 125, Issue 16, 2015, Pages 2455-2456

  Forconi, Francesco ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; IBRUTINIB; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN M; INTERLEUKIN 10; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CELL ADHESION; CELL DEATH; CELL MIGRATION; CHRONIC LYMPHATIC LEUKEMIA; CIRCULATING TUMOR CELL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; GENE MUTATION; HUMAN; LEUKEMIA REMISSION; LYMPHOCYTOSIS; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; TH1 CELL; TREATMENT DURATION; FEMALE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE;

FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; PYRAZOLES; PYRIMIDINES;

EID: 84927723187     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-03-630772     Document Type: Note

References (8)

1. Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497-2506.
2. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
3. Cheng S, Ma J, Guo A, et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 2014;28(3):649-657.
4. Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123(12):1810-1817.
5. Packham G, Krysov S, Allen A, et al. The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy. Haematologica. 2014;99(7):1138-1148.
6. Coelho V, Krysov S, Steele A, et al. Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function. Blood. 2013;122(15):2664-2672.
7. Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13):2062-2067.
8. DiLillo DJ, Weinberg JB, Yoshizaki A, et al. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia. 2013;27(1):170-182.